Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Faeth Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- −1 vs. Q1 2023
- Shares held
- 3.14M
- +8.06K (+0.3%) vs. Q1 2023
- Total value
- $3.58M
- −$1.12M (−23.9%) vs. Q1 2023
- New holders
- 1
- 6 more added
- Sold out
- 2
- 6 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $333.8M |
| Q1 2026 | 30 | $68.0M |
| Q4 2025 | 10 | $514.8K |
| Q3 2025 | 9 | $466.2K |
| Q2 2025 | 10 | $600.0K |
| Q1 2025 | 20 | $760.2K |
| Q4 2024 | 24 | $1.16M |
| Q3 2024 | 19 | $1.32M |
| Q2 2024 | 24 | $1.31M |
| Q1 2024 | 25 | $2.43M |
| Q4 2023 | 24 | $2.05M |
| Q3 2023 | 23 | $2.38M |
| Q2 2023 | 26 | $3.58M |
| Q1 2023 | 27 | $4.71M |
| Q4 2022 | 28 | $3.93M |
| Q3 2022 | 31 | $4.47M |
| Q2 2022 | 40 | $7.06M |
| Q1 2022 | 43 | $8.21M |
| Q4 2021 | 38 | $19.7M |
| Q3 2021 | 42 | $37.1M |
| Q2 2021 | 34 | $22.7M |
| Q1 2021 | 40 | $45.8M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Faeth Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Harbour Investments, Inc. | 3 | $3 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 8 | $9 | 0.00% | +8 | New |
| Wells Fargo & Company | 132 | $150 | 0.00% | +7+5.6% | Added |
| Morgan Stanley | 219 | $250 | 0.00% | −128,425−99.8% | Reduced |
| JPMorgan Chase & Co | 668 | $762 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 472 | $1.00K | 0.00% | +411+673.8% | Added |
| Banque Cantonale Vaudoise | 3,900 | $4.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 6,511 | $7.42K | 0.00% | +3,071+89.3% | Added |
| Tower Research Capital LLC (TRC) | 7,470 | $8.52K | 0.00% | +5,515+282.1% | Added |
| Deuterium Capital Management, LLC | 11,000 | $12.5K | 0.02% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 11,570 | $13.2K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 13,576 | $15.5K | 0.00% | −1,700−11.1% | Reduced |
| Raymond James & Associates | 14,000 | $16.0K | 0.00% | 00.0% | Unchanged |
| BFT Financial Group, LLC | 14,845 | $16.9K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 24,900 | $28.4K | 0.00% | −1,400−5.3% | Reduced |
| State Street Corp | 25,774 | $29.4K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 26,049 | $29.7K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 36,667 | $41.8K | 0.00% | −1,442−3.8% | Reduced |
| Millennium Management LLC | 54,210 | $61.8K | 0.00% | −15,981−22.8% | Reduced |
| Renaissance Technologies LLC | 89,500 | $102.0K | 0.00% | −35,700−28.5% | Reduced |
| Bank of America Corp | 90,774 | $103.5K | 0.00% | +788+0.9% | Added |
| Geode Capital Management, LLC | 98,006 | $111.7K | 0.00% | 00.0% | Unchanged |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 100,000 | $114.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 112,900 | $128.7K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 573,651 | $654.0K | 0.00% | 00.0% | Unchanged |
| Newtyn Management, LLC | 1,827,240 | $2.08M | 0.49% | +286,320+18.6% | Added |
| Bank of Montreal | 0 | $0 | 0.00% | −87,892−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −15,521−100.0% | Sold out |